Extracts and Constituents of Hypericum Perforatum Inhibit the Binding of Various Ligands to Recombinant Receptors Expressed with the Semliki Forest Virus System

References

• Linde K., Ramirez G., Mulrow C. D., Pauls A., Weidenhammer W., Melchart D. St John's wort for depression - an overview and meta-analysis of randomised clinical trials. Br. Med. J. 1996; 313: 253–258
   PubMed Web of Science ®Google Scholar
• Sparenberg B., Demisch L., Hölzl J. Untersuchungen über antidepressive Wirkstoffe von Johanniskraut. Pharm. Ztg. Wiss. 1993; 2(6)50–54
   Google Scholar
• Thiede H. M., Walper A. MAO- und COMT-Hemmung durch Hypericum-Extrakte und Hypericin. Nervenheilkunde 1993; 12: 346–348
   Google Scholar
• Perovic S., Müller W. E. G. Pharmacological profile of Hypericum extract. Arzneim.-Forsch. 1995; 45: 1145–1148
   PubMed Web of Science ®Google Scholar
• Müller W. E., Schäfer C. Johanniskraut. Deutsche Apotheker Zeitung. 1996; 13: 17–24
   Google Scholar
• Müller W. E., Rolli M., Schäfer C., Hafner U. Effects of Hypericum extract (LI 160) in biochemical models of antidepressant activity. Pharmacopsychiat. 1997; 30: 102–107, Suppl
   PubMed Web of Science ®Google Scholar
• Teufel-Mayer R., Gleitz J. Effects of long-term administration of Hypericum extracts on the affinity and density of the central serotonergic 5-HT1A and 5-HT2A receptors. Pharmacopsychiat. 1997; 30: 113–116, Suppl
   PubMed Web of Science ®Google Scholar
• Winterhoff H., Butterweck V., Nahrstedt A., Gumbinger H. G., Schulz V., Erping S., Bosshammer F., Wieligmann A. Pharmakologische Untersuchungen zur antidepressiven Wirkung von Hypericum perforatum L. Phytopharmaka in Forschung und klinischer Anwendung, D. Loew, N. Riehbrock. Steinkopf Verlag, Darmstadt 1995; 39–56
   Google Scholar
• Thiele B., Brink I., Ploch M. Modulation of cytokine expression by Hypericum extract. J. Ger. Psych. Neurol. 1993; 7: 60–62, Suppl
   Google Scholar
• Chatterjee S. S., Koch E., Nöldner M., Biber A., Erdelmeier C. Hyperforin and Hypericum extract: Interactions with some neurotransmitter systems. 2nd Internat. Congress on Phytomedicine. Munich 1996
   Google Scholar
• Nielsen M., Frokjaer S., Braestrub C. High affinity of the naturally-occurring biflavonoid, amentoflavon, to brain benzodiazepine receptors in vitro. Biochem. Pharmacol. 1988; 37: 3285–3287
   PubMed Web of Science ®Google Scholar
• Baureithel K. H., Berger Büter K., Engesser A., Burkard W., Schaffner W. Inhibition of benzodiazepine binding in vitro by amentoflavon, a constituent of various species of Hypericum. Pharmac. Acta Helvetiae 1997; 72: 153–157
   PubMedGoogle Scholar
• Cott J. M. In vitro receptor binding and enzyme inhibition by Hypericum perforatum extract. Pharmacopsychiat. 1997; 30: 108–112, Suppl
   PubMed Web of Science ®Google Scholar
• Simmen U., Schweitzer C., Burkard W., Schaffner W., Lundstrom K. Hypericum perforatum inhibits the binding of μ- and -opioid receptors expressed with the Semliki Forest virus system. Pharmac. Acta Helvetiae. 1998, In press
   PubMedGoogle Scholar
• Pfeiffer A., Brantl V., Herz A., Emrich H. M. Psychotomimesis mediated by opiate receptors. Science 1986; 233: 774–776
   PubMed Web of Science ®Google Scholar
• Pasternak G. W. Pharmacological mechanisms of opioid analgesics. Clin. Neuropharmacology 1993; 16: 1–18
   PubMed Web of Science ®Google Scholar
• Bot G., Blake A. D., Li S., Reisine T. Opioid regulation of the mouse delta-opioid receptor expressed in human embryonic kidney 293 cells. Mol. Pharmacol. 1997; 52: 272–281
   PubMed Web of Science ®Google Scholar
• Sumner B., Fink G. Estrogen increases the density of 5-Hydroxy-tryptamine2A receptors in cerebral cortex and nucleus accumbens in the female rat. J. Steroid Biochem. Molec. Biol. 1995; 54: 15–20
   PubMed Web of Science ®Google Scholar
• Sleight A. J., Boess F. G., Bourson A., Sibley D. R., Monsma F. J., Jr. 5-HT6 and 5-HT7 receptors: Molecular biology, functional correlates and possible therapeutic indications. DN&P 1997; 10: 214–224
   Google Scholar
• Maggi C. A., Patacchini R., Rovero P., Giachetti A. Tachykinin receptors and tachykinin receptor antagonists. J. Auton. Pharmacol. 1993; 13: 23–93
   PubMedGoogle Scholar
• Khawaja A. M., Rogers D. F. Tachykinins: receptor to effector. Int. J. Biochem. Cell Biol. 1996; 28: 721–738
   PubMed Web of Science ®Google Scholar
• Zhu M., Phillipson D., Greengrass P. M., Bowery N. E., Cai Y. Plant polyphenols: Biologically active compounds or non-selective binders to protein?. Phytochemistry 1997; 44: 441–447
   PubMed Web of Science ®Google Scholar
• Lundstrom K., Hawcock A. B., Vargas A., Ward P., Thomas P., Naylor A. Effect of single point mutations of the human tachykinin NK1 receptor on antagonist affinity. Eur. J. Pharmacol. 1997; 337: 73–81
   PubMed Web of Science ®Google Scholar
• Berglund P., Sjöberg M., Garoff H., Atkins J. G., Sheahan B. J., Liljeström P. Semliki Forest Virus expression system: Production of conditionally infectious recombinant particles. Bio/Technology 1993; 11: 916–920
   PubMed Web of Science ®Google Scholar
• Lundstrom K., Mills A., Buell G., Allet E., Adami N., Liljestrom P. High-level expression of the human neurokinin-1 receptor in mammalian cell lines using the Semliki Forest virus expression system. Eur. J. Biochem. 1994; 224: 917–921
   PubMedGoogle Scholar
• Smith P. K., Krohn R. I., Hermanson G. T., Mallia A. K., Gartner F. H., Provenzano M. D., Fujimoto E. K., Goeke N. M., Olson B. J., Klenk D. C. Measurement of protein using bicinchoninic acid. Anal. Biochem. 1985; 150: 76–85
   PubMed Web of Science ®Google Scholar
• Miksicek R. J. Estrogenic flavonoids: Structural requirements for biological activity. Proceed. Soc. Exp. Biol. Med. 1995; 208: 44–50
   PubMed Web of Science ®Google Scholar